Clinical importance of respiratory muscle fatigue in patients with cardiovascular disease.


Journal

Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R

Informations de publication

Date de publication:
21 Aug 2020
Historique:
entrez: 28 8 2020
pubmed: 28 8 2020
medline: 9 9 2020
Statut: ppublish

Résumé

Patients with cardiovascular diseases frequently experience exertional dyspnea. However, the relationship between respiratory muscle strength including its fatigue and cardiovascular dysfunctions remains to be clarified.The maximal inspiratory pressure/maximal expiratory pressure (MIP/MEP) before and after cardiopulmonary exercise testing (CPX) in 44 patients with heart failure and ischemic heart disease were measured. Respiratory muscle fatigue was evaluated by calculating MIP (MIPpost/MIPpre) and MEP (MEPpost/MEPpre) changes.The mean MIPpre and MEPpre values were 67.5 ± 29.0 and 61.6 ± 23.8 cm H2O, respectively. After CPX, MIP decreased in 25 patients, and MEP decreased in 22 patients. We evaluated the correlation relationship between respiratory muscle function including respiratory muscle fatigue and exercise capacity evaluated by CPX such as peak VO2 and VE/VCO2 slope. Among MIP, MEP, change in MIP, and change in MEP, only the value of change in MIP had an association with the value of VE/VCO2 slope (R = -0.36, P = .017). In addition, multivariate analysis for determining factor of change in MIP revealed that the association between the change in MIP and eGFR was independent from other confounding parameters (beta, 0.40, P = .017). The patients were divided into 2 groups, with (MIP change < 0.9) and without respiratory muscle fatigue (MIP change > 0.9), and a significant difference in peak VO2 (14.2 ± 3.4 [with fatigue] vs 17.4 ± 4.7 [without fatigue] mL/kg/min; P = .020) was observed between the groups.Respiratory muscle fatigue demonstrated by the change of MIP before and after CPX significantly correlated with exercise capacity and renal function in patients with cardiovascular disease.

Identifiants

pubmed: 32846812
doi: 10.1097/MD.0000000000021794
pii: 00005792-202008210-00066
pmc: PMC7447364
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e21794

Références

Circulation. 2009 Jun 30;119(25):3189-97
pubmed: 19528334
J Intern Med. 2004 Jan;255(1):115-24
pubmed: 14687247
Eur Respir Rev. 2016 Sep;25(141):317-32
pubmed: 27581831
Am J Respir Crit Care Med. 2011 May 15;183(10):1302-10
pubmed: 21257789
Respir Physiol Neurobiol. 2006 Apr 28;151(2-3):242-50
pubmed: 16616716
Am Rev Respir Dis. 1990 Aug;142(2):474-80
pubmed: 2382912
Respir Care. 2009 Oct;54(10):1321-8
pubmed: 19796411
Nutr Metab (Lond). 2015 Nov 25;12:49
pubmed: 26612997
Heart Vessels. 2018 Jul;33(7):752-759
pubmed: 29335797
PLoS One. 2013;8(3):e60119
pubmed: 23533671
J Appl Physiol (1985). 2018 Jan 1;124(1):208-224
pubmed: 29051336
J Card Fail. 2017 Nov;23(11):777-782
pubmed: 28736291
J Appl Physiol (1985). 2008 Mar;104(3):879-88
pubmed: 18096752
Exp Physiol. 2013 Dec;98(12):1705-17
pubmed: 24014807
Am J Physiol Heart Circ Physiol. 2015 Nov;309(9):H1419-39
pubmed: 26320036
PLoS One. 2013 Dec 06;8(12):e83432
pubmed: 24324843
Br Heart J. 1995 Jul;74(1):27-33
pubmed: 7662449
Curr Heart Fail Rep. 2009 Jun;6(2):95-101
pubmed: 19486593
Int J Cardiol Heart Vasc. 2019 Jan 08;22:84-91
pubmed: 30671533
Kidney Int. 2000 Aug;58(2):867-72
pubmed: 10916112
PLoS One. 2015 Feb 11;10(2):e0118218
pubmed: 25671566
ESC Heart Fail. 2018 Dec;5(6):1074-1082
pubmed: 30570227
Circulation. 1999 Aug 3;100(5):503-8
pubmed: 10430764
Prog Cardiovasc Dis. 1995 May-Jun;37(6):347-70
pubmed: 7777667
BBA Clin. 2014 Jun 1;1:12-23
pubmed: 25147756

Auteurs

Masanobu Taya (M)

Department of Cardiovascular Medicine, Graduate School of Medicine, the University of Tokyo.
Department of Rehabilitation Medicine, the University of Tokyo Hospital.

Eisuke Amiya (E)

Department of Cardiovascular Medicine, Graduate School of Medicine, the University of Tokyo.
Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo.

Masaru Hatano (M)

Department of Cardiovascular Medicine, Graduate School of Medicine, the University of Tokyo.
Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo.

Akihito Saito (A)

Department of Cardiovascular Medicine, Graduate School of Medicine, the University of Tokyo.

Daisuke Nitta (D)

Department of Cardiovascular Medicine, Graduate School of Medicine, the University of Tokyo.

Hisataka Maki (H)

Department of Cardiovascular Medicine, Graduate School of Medicine, the University of Tokyo.

Yumiko Hosoya (Y)

Department of Cardiovascular Medicine, Graduate School of Medicine, the University of Tokyo.
Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo.

Shun Minatsuki (S)

Department of Cardiovascular Medicine, Graduate School of Medicine, the University of Tokyo.

Masaki Tsuji (M)

Department of Cardiovascular Medicine, Graduate School of Medicine, the University of Tokyo.

Tatsuyuki Sato (T)

Department of Cardiovascular Medicine, Graduate School of Medicine, the University of Tokyo.

Haruka Murakami (H)

Department of Cardiovascular Medicine, Graduate School of Medicine, the University of Tokyo.

Koichi Narita (K)

Department of Cardiovascular Medicine, Graduate School of Medicine, the University of Tokyo.

Yuto Konishi (Y)

Department of Cardiovascular Medicine, Graduate School of Medicine, the University of Tokyo.
Department of Rehabilitation Medicine, the University of Tokyo Hospital.

Shogo Watanabe (S)

Department of Medical Technology, Graduate School of Health Sciences, Okayama University, Okayama Prefecture, Japan.

Kazuhiko Yokota (K)

Department of Rehabilitation Medicine, the University of Tokyo Hospital.

Nobuhiko Haga (N)

Department of Rehabilitation Medicine, the University of Tokyo Hospital.

Issei Komuro (I)

Department of Cardiovascular Medicine, Graduate School of Medicine, the University of Tokyo.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH